This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Smits, M. G. Articles by Kerkhof, G. A. Search for Related Content PubMed PubMed Citation Articles by Smits, M. G. Articles by Kerkhof, G. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Melatonin for Chronic Sleep Onset Insomnia in Children: A Randomized Placebo-Controlled Trial

Department of Neurology and Sleep-Wake Disorders Hospital De Gelderse Vallei, Ede

Elsbeth E. Nagtegaal, PharmD

Department of Clinical Pharmacy Eemland Hospital Amersfoort

Janine van der Heijden, MSc

Department of Psychology, Nijmegen Institute for Cognitive Information, University of Nijmegen

Anton M.L. Coenen, PhD

Department of Psychology, Nijmegen Institute for Cognitive Information, University of Nijmegen

Gerard A. Kerkhof, PhD

Sleep/Wake Disorders Center Medical Center Haaglanden, Westeinde, The Hague, Department of Psychology, University of Leiden, Department of Psychology, University of Amsterdam, The Netherlands

To establish the efficacy of melatonin treatment in childhood sleep onset insomnia, 40 elementary school children, 6 to 12 years of age, who suffered more than 1 year from chronic sleep onset insomnia, were studied in a double-blind, placebo-controlled study. The children were randomly assigned to receive either 5-mg melatonin or placebo. The study consisted of a 1-week baseline, consecutively followed by a 4-week treatment period. After that period, treatment was continued if the parents wished so. The study's impact was assessed by measurements of lights-off time, sleep onset, and wake-up time, recorded in a diary (n = 33). Sleep onset was also recorded with an actigraph (n = 25). Endogenous dim light melatonin onset was measured in saliva (n = 27). Sustained attention was evaluated with the Bourdon-Vos reaction time test (n = 36). In the melatonin group, mean (95% CI) lights-off time advanced 34 (6-63) minutes, diary sleep onset 63 (32-94) minutes, actigraphic sleep onset 75 (36-114) minutes, and melatonin onset 57 (24 to 89) minutes; total sleep time increased 41 (19-62) minutes. In the placebo group, these parameters did not shift significantly. The change during the 4-week treatment period differed between the treatment groups significantly as to lights-off time, diary and actigraphic sleep onset, sleep duration, and melatonin onset. There were no significant differences between the treatment groups in the change of sleep latency, wake-up time, and sustained attention reaction times. Mild headache occurred in 2 children during the first 2 days of the melatonin treatment. Eighteen months after the start of the trial, in 13 of the 38 children who could be followed up, melatonin treatment was stopped because their sleep problem was solved and in 1 child because sleep was not improved. Twelve children used melatonin 5 mg, the other 1.0 to 2.5 mg. One child developed mild generalized epilepsy 4 months after the start of the trial. The results show that melatonin, 5 mg at 6 PM, was relatively safe to take in the short term and significantly more effective than placebo in advancing sleep onset and dim light melatonin onset and increasing sleep duration in elementary school children with chronic sleep onset insomnia. Sustained attention was not affected. (J Child Neurol 2001;16:86-92).

Journal of Child Neurology, Vol. 16, No. 2, 86-92 (2001)
DOI: 10.1177/088307380101600204


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Shamseer and S. Vohra Complementary, Holistic, and Integrative Medicine: Melatonin Pediatr. Rev., June 1, 2009; 30(6): 223 - 228. [Full Text] [PDF]

				J. Quach, H. Hiscock, L. Canterford, and M. Wake Outcomes of Child Sleep Problems Over the School-Transition Period: Australian Population Longitudinal Study Pediatrics, May 1, 2009; 123(5): 1287 - 1292. [Abstract] [Full Text] [PDF]

				P Gringras When to use drugs to help sleep Arch. Dis. Child., November 1, 2008; 93(11): 976 - 981. [Abstract] [Full Text] [PDF]

				W. Braam, R. Didden, M. G. Smits, and L. M. G. Curfs Melatonin for Chronic Insomnia in Angelman Syndrome: A Randomized Placebo-Controlled Trial J Child Neurol, June 1, 2008; 23(6): 649 - 654. [Abstract] [PDF]

				A. Szeinberg, K. Borodkin, and Y. Dagan Melatonin Treatment in Adolescents With Delayed Sleep Phase Syndrome Clinical Pediatrics, November 1, 2006; 45(9): 809 - 818. [Abstract] [PDF]

				K. B. van der Heijden, M. G. Smits, and W. B. Gunning Sleep-related Disorders in ADHD: A Review Clinical Pediatrics, April 1, 2005; 44(3): 201 - 210. [PDF]

				D. Armour and C. Paton Melatonin in the treatment of insomnia in children and adolescents Psychiatr. Bull., June 1, 2004; 28(6): 222 - 224. [Abstract] [Full Text] [PDF]

				A. Ivanenko, V. M. Crabtree, R. Tauman, and D. Gozal Melatonin in Children and Adolescents with Insomnia: A Retrospective Study Clinical Pediatrics, January 1, 2003; 42(1): 51 - 58. [Abstract] [PDF]